Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice

BACKGROUND/OBJECTIVE: Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Stohl, William, Yu, Ning, Chalmers, Samantha A, Putterman, Chaim, Jacob, Chaim O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519407/
https://www.ncbi.nlm.nih.gov/pubmed/31168399
http://dx.doi.org/10.1136/lupus-2018-000313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519407/
https://www.ncbi.nlm.nih.gov/pubmed/31168399
http://dx.doi.org/10.1136/lupus-2018-000313

Ejemplares similares